Medline Reports Strong Q4 Sales Growth, Provides 2026 Guidance

summarizeSummary

Medline Inc. reported strong sales growth for Q4 and full year 2025, alongside a decrease in net income attributed to tariffs and IPO-related costs, while providing positive 2026 guidance.

check_boxKey Events

• Fourth Quarter 2025 Performance

  Net sales increased by 14.8% to $7.8 billion, while net income decreased by 37.7% to $180 million. Adjusted EBITDA was approximately flat at $805 million.

• Full Year 2025 Performance

  Net sales grew 11.5% to $28.4 billion. Net income saw a slight decrease of 3.6% to $1.2 billion, but Adjusted EBITDA increased by 3.2% to $3.5 billion.

• 2026 Financial Guidance

  The company expects full year 2026 organic sales growth of 8% to 9% and Adjusted EBITDA in the range of $3.5 billion to $3.6 billion.

• Impact of Costs and IPO

  The decline in net income was primarily driven by higher costs of goods sold due to tariffs and increased operating costs, including investments in headcount and expenses related to the company's initial public offering.

auto_awesomeAnalysis

Medline Inc. announced its fourth quarter and full year 2025 results, showcasing robust sales growth but a decline in net income. The company's net sales increased by 14.8% in Q4 2025 and 11.5% for the full year, driven by increased volumes across both its Medline Brand and Supply Chain Solutions segments. While net income decreased, primarily due to higher costs of goods sold from tariffs and increased operating costs including IPO-related expenses and headcount investments, Adjusted EBITDA remained relatively stable in Q4 and grew for the full year. The company also provided 2026 guidance, projecting organic sales growth of 8% to 9% and Adjusted EBITDA between $3.5 billion and $3.6 billion, indicating continued operational strength and a positive outlook following its successful initial public offering.